A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis
View ORCID ProfileRuth Dobson, David Holden, Nicola Vickaryous, Jonathan Bestwick, Katila George, Tatiana Sayali, Lucia Bianchi, Mohammad Wafa, Julian Gold, Gavin Giovannoni
doi: https://doi.org/10.1101/2023.08.18.23294265
Ruth Dobson
1Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London
2Department of Neurology, Royal London Hospital, Barts Health NHS Trust
David Holden
3Blizard Institute, Queen Mary University London
Nicola Vickaryous
1Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London
Jonathan Bestwick
1Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London
Katila George
1Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London
2Department of Neurology, Royal London Hospital, Barts Health NHS Trust
Tatiana Sayali
2Department of Neurology, Royal London Hospital, Barts Health NHS Trust
Lucia Bianchi
2Department of Neurology, Royal London Hospital, Barts Health NHS Trust
4Department of Brain Sciences, Imperial College London
Mohammad Wafa
2Department of Neurology, Royal London Hospital, Barts Health NHS Trust
Julian Gold
5The Albion Centre, University of Sydney School of Medicine, Sydney
Gavin Giovannoni
2Department of Neurology, Royal London Hospital, Barts Health NHS Trust
3Blizard Institute, Queen Mary University London
Data availability
Anonymised participant-level data is available from the authors on request
Posted August 20, 2023.
A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis
Ruth Dobson, David Holden, Nicola Vickaryous, Jonathan Bestwick, Katila George, Tatiana Sayali, Lucia Bianchi, Mohammad Wafa, Julian Gold, Gavin Giovannoni
medRxiv 2023.08.18.23294265; doi: https://doi.org/10.1101/2023.08.18.23294265
A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis
Ruth Dobson, David Holden, Nicola Vickaryous, Jonathan Bestwick, Katila George, Tatiana Sayali, Lucia Bianchi, Mohammad Wafa, Julian Gold, Gavin Giovannoni
medRxiv 2023.08.18.23294265; doi: https://doi.org/10.1101/2023.08.18.23294265
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (691)
- Anesthesia (185)
- Cardiovascular Medicine (2781)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12432)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4299)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4074)
- Nursing (218)
- Nutrition (603)
- Oncology (2155)
- Ophthalmology (609)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (474)
- Public and Global Health (6680)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)